Lunai Bioworks Inc.
For the period ended Jun 30, 2026. Filed Oct 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Oct 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Part I
Unless otherwise indicated or the context otherwise requires, all references in this Annual Report to “we,” “us,” “our,” “Lunai” or the “Company” are toLunai Bioworks Inc., a Delaware corporation together with its wholly owned subsidiaries, Renovaro Biosciences, Inc., a Delaware corporation (“Renovaro Biosciences”), GEDi Cube Intl Ltd, a private limited company incorporated under the laws of England and Wales (“GEDi Cube UK”), Grace Systems B.V., a Dutch private limited company, Renovaro Biosciences Denmark ApS, a Danish limited company, organized under the Danish Act on Limited Companies of the Kingdom of Denmark, BioSymetrics Inc., a Delaware Corporation, BioSymetrics Corp., an unlimited company registered under the laws of Nova Scotia, and Lunai Bioworks IP, Inc., a Delaware corporation. GEDi Cube B.V., a former indirect Dutch subsidiary, was deconsolidated following its bankruptcy in September 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.